Table 5.
Summary of subject baseline demographics
| Treatment Groups | |||||
|---|---|---|---|---|---|
| 0.1% NVC-422 n = 41 | 0.5% NVC-422 n = 43 | 1.5% NVC-422 n=41 | P-value | ||
| Age (years) | Mean ± SD | 4.9 ± 2.8 | 4.8 ± 2.4 | 4.7 ±2.7 | 0.9631 |
| Range | 2.0-11.3 | 2.0-11.32.0-1 | 2.0-11.4 | ||
| Gender | Female | 28 (68.3%) | 20 (46.5%) | 17 (41.5%) | 0.0362 |
| Male | 13 (31.7%) | 23 (53.5%) | 24 (58.5%) | ||
| Race | Black/African American | 14 (34.2%) | 20 (46.5%) | 14 (34.2%) | 0.0992 |
| White | 4 (9.8%) | 5 (11.6%) | 0 (0.0%) | ||
| Other | 23 (56.1%) | 20 (46.5%) | 18 (41.9%) | ||
| Infecting Organism | S. aureus | 33 (80.5%) | 40 (93.0%) | 33 (80.5%) | 0.0142 |
| S. pyogenes | 4 (9.8%) | 3 (7.0%) | 0 (0.0%) | ||
| Both | 4 (9.8%) | 0 (0.0%) | 8 (19.5%) | ||
| Exudate/Pus | 0 (Absent) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0.0042 |
| 1 (Mild) | 23 (56.1%) | 36 (83.7%) | 21 (51.2%) | ||
| 2 (Moderate) | 18 (43.9%) | 7 (16.3%) | 20 (48.8%) | ||
| 3 (Severe) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Total SIRS | Mean ± SD | 7.12 ± 1.49 | 6.88 ± 1.35 | 7.63 ±1.64 | 0.0681 |
| Range | 4-10 | 4-10 | 4-11 | ||
1
P-values for treatment comparisons from a one-way ANOVA with factor of treatment
2
P-values for treatment comparisons from CMH tests for general association